View all newsletters
Eli Lilly and Company has announced that its drug ramucirumab has not succeeded in improving the survival rate of metastatic breast cancer patients in its Phase…
ByUS-based biotechnology company Dendreon Corporation has received marketing authorisation from the European Commission (EC) for its prostate cancer treatment,…
ByMultiple sclerosis (MS) drug alemtuzumab, marketed under the brand name Lemtrada, has been approved by the European Medicines Agency…
BySanofi and its subsidiary Genzyme have been given marketing approval by the European Commission for Lemtrada (alemtuzumab), a treatment…
ByColumbia Laboratories has purchased UK-based Molecular Profiles, a pharmaceutical formula developer and manufacturer, for an estimated $25m.
ByRoche has reached a licence agreement with US-based Inovio Pharmaceuticals to develop and promote Inovio's multi-antigen DNA immunotherapies for…
ByUS-based Celgene Corporation's chemotherapy drug Abraxane has received approval by the US Food and Drug Administration (FDA) for the…
ByBayer HealthCare has submitted an application to the European Medicines Agency (EMA) for marketing authorisation regarding the oral multi-kinase…
ByAn experimental drug from GlaxoSmithKline has been unsuccessful in a late-stage clinical test to treat patients with melanoma.
ByThank you for subscribing to Pharmaceutical Technology